September 9, 2019
FOR IMMEDIATE RELEASE:
Microbiome Labs is excited to announce the publication of their most recent study, “Bacillus spp. Spores—A Promising Treatment Option for Patients with Irritable Bowel Syndrome.” This prospective, randomized clinical study took place at a medical center in Romania and included 90 patients with irritable bowel syndrome (IBS). Subjects were separated into three groups of 30 and given one of three treatments for 34 days.
The first group received 10 days of antibiotic treatment with Rifaximin, followed by 24 days of a nutraceutical containing Bifidobacterium longum, prebiotics, and vitamins. The second group received MegaSporeBioticTM for 34 days, and the third group received 10 days of antibiotic treatment with Rifaximin, followed by 24 days of a low-FODMAP (fermentable oligo-, di-, monosaccharides and polyols) diet. IBS severity scores, quality of life, and rectal volume sensation were measured at days 1, 10, 34, and 60.
IBS severity scores examined the severity of abdominal pain and the number of days with pain or distention, as well as the impact of each on quality of life. Quality of life evaluated functional status (physical and social functioning and physical and emotional problems), well-being (mental health, vitality, and pain), and general health assessment (general perception of health). Rectal volume sensation tests are conducted with expanding balloon catheters to measure sensory thresholds, which, when elevated, are characteristic of constipation and fecal incontinence.
The results showed that treatment with MegaSporeBiotic™ reduced the IBS severity score more effectively than Rifaximin with the nutraceutical and similarly to Rifaximin with the low-FODMAP diet. MegaSporeBiotic™ had a similar beneficial effect on rectal volume sensation to the other treatments, and a significantly better effect on the quality of life compared with Rifaximin plus the nutraceutical or a low-FODMAP diet. If IBS is linked to dysbiosis, these results demonstrate that MegaSporeBiotic™ has the capacity to reduce gut dysbiosis to a similar degree as antibiotic treatment.
To view the study, click the link below:
To learn more about MegaSporeBiotic™, click the link below:
Director of Marketing